We suggest that MLGZG has a protective role in NASH treatment via suppression of TLR-4-mediated inflammation activation, which subsequently reduces lipid accumulation in the liver. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatohepatitis.